{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:06:16Z","timestamp":1791111976509,"version":"4.1.0"},"reference-count":86,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,11]]},"DOI":"10.1097\/ppo.0b013e318159467b","type":"journal-article","created":{"date-parts":[[2008,5,4]],"date-time":"2008-05-04T08:36:50Z","timestamp":1209890210000},"page":"366-371","source":"Crossref","is-referenced-by-count":27,"title":["JAK2 Mutations and Clinical Practice in Myeloproliferative Neoplasms"],"prefix":"10.1097","volume":"13","author":[{"given":"Ayalew","family":"Tefferi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210203","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Some speculations on the myeloproliferative syndromes.","volume":"6","author":"Dameshek","year":"1951","journal-title":"Blood"},{"key":"R2-5-20210203","doi-asserted-by":"crossref","first-page":"6848","DOI":"10.1073\/pnas.88.15.6848","article-title":"Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction.","volume":"88","author":"Gilliland","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"R3-5-20210203","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1073\/pnas.58.4.1468","article-title":"Clonal origin of chronic myelocytic leukemia in man.","volume":"58","author":"Fialkow","year":"1967","journal-title":"Proc Natl Acad Sci USA"},{"key":"R4-5-20210203","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJM197308092890608","article-title":"Clonal origin of chronic myelocytic leukemia.","volume":"289","author":"Barr","year":"1973","journal-title":"N Engl J Med"},{"key":"R5-5-20210203","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJM197610212951702","article-title":"Polycythemia vera: stem-cell and probable clonal origin of the disease.","volume":"295","author":"Adamson","year":"1976","journal-title":"N Engl J Med"},{"key":"R6-5-20210203","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0002-9343(77)90124-3","article-title":"Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte\/macrophage.","volume":"63","author":"Fialkow","year":"1977","journal-title":"Am J Med"},{"key":"R7-5-20210203","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1172\/JCI109193","article-title":"Chronic myelocytic leukemia: origin of some lymphocytes from leukemic stem cells.","volume":"62","author":"Fialkow","year":"1978","journal-title":"J Clin Invest"},{"key":"R8-5-20210203","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1182\/blood.V51.2.189.189","article-title":"Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis.","volume":"51","author":"Jacobson","year":"1978","journal-title":"Blood"},{"key":"R9-5-20210203","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/287049a0","article-title":"Involvement of the B-lymphoid system in chronic myelogenous leukaemia.","volume":"287","author":"Martin","year":"1980","journal-title":"Nature"},{"key":"R10-5-20210203","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1182\/blood.V58.5.916.916","article-title":"Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell.","volume":"58","author":"Fialkow","year":"1981","journal-title":"Blood"},{"key":"R11-5-20210203","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1182\/blood-2002-07-2341","article-title":"Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia.","volume":"101","author":"Reeder","year":"2003","journal-title":"Blood"},{"key":"R12-5-20210203","first-page":"85","article-title":"A minute chromosome in human chronic granulocytic leukemia.","volume":"25","author":"Nowell","year":"1960","journal-title":"J Natl Cancer Inst"},{"key":"R13-5-20210203","doi-asserted-by":"crossref","first-page":"6649","DOI":"10.1073\/pnas.87.17.6649","article-title":"Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR\/ABL.","volume":"87","author":"Kelliher","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"R14-5-20210203","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome.","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"key":"R15-5-20210203","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/j.1460-2075.1990.tb08212.x","article-title":"bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice.","volume":"9","author":"Elefanty","year":"1990","journal-title":"EMBO J"},{"key":"R16-5-20210203","doi-asserted-by":"crossref","first-page":"550","DOI":"10.4161\/cc.6.5.3919","article-title":"Oncogenes in myeloproliferative disorders.","volume":"6","author":"Tefferi","year":"2007","journal-title":"Cell Cycle"},{"key":"R17-5-20210203","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"R18-5-20210203","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"R19-5-20210203","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain of function mutation in Jak2 is frequently found in patients with myeloproliferative disorders.","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"R20-5-20210203","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"R21-5-20210203","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"key":"R22-5-20210203","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/sj.leu.2404810","article-title":"Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.","volume":"21","author":"Pardanani","year":"2007","journal-title":"Leukemia"},{"key":"R23-5-20210203","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"key":"R24-5-20210203","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"R25-5-20210203","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/35077225","article-title":"Oncogenic kinase signalling.","volume":"411","author":"Blume-Jensen","year":"2001","journal-title":"Nature"},{"key":"R26-5-20210203","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0092-8674(00)00114-8","article-title":"Cell signaling by receptor tyrosine kinases.","volume":"103","author":"Schlessinger","year":"2000","journal-title":"Cell"},{"key":"R27-5-20210203","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1038\/sj.onc.1203957","article-title":"The protein tyrosine kinase family of the human genome.","volume":"19","author":"Robinson","year":"2000","journal-title":"Oncogene"},{"key":"R28-5-20210203","doi-asserted-by":"crossref","first-page":"13023","DOI":"10.1073\/pnas.91.26.13023","article-title":"Human thrombopoietin: gene structure, cDNA sequence, expression, and chromosomal localization.","volume":"91","author":"Foster","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"R29-5-20210203","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/BF00286717","article-title":"The human homolog of the myeloproliferative virus maps to chromosome band 1p34.","volume":"83","author":"Le Coniat","year":"1989","journal-title":"Hum Genet"},{"key":"R30-5-20210203","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0092-8674(00)81167-8","article-title":"Jak2 is essential for signaling through a variety of cytokine receptors.","volume":"93","author":"Parganas","year":"1998","journal-title":"Cell"},{"key":"R31-5-20210203","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/gene.20063","article-title":"Generation of a conditional knockout allele for the Janus kinase 2 (Jak2) gene in mice.","volume":"40","author":"Krempler","year":"2004","journal-title":"Genesis"},{"key":"R32-5-20210203","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1182\/blood.V90.7.2535","article-title":"Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15:12) in a myeloid leukemia.","volume":"90","author":"Peeters","year":"1997","journal-title":"Blood"},{"key":"R33-5-20210203","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1126\/science.278.5341.1309","article-title":"A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia.","volume":"278","author":"Lacronique","year":"1997","journal-title":"Science"},{"key":"R34-5-20210203","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1158\/0008-5472.CAN-04-4263","article-title":"The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2.","volume":"65","author":"Reiter","year":"2005","journal-title":"Cancer Res"},{"key":"R35-5-20210203","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1038\/sj.leu.2403879","article-title":"PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation.","volume":"19","author":"Murati","year":"2005","journal-title":"Leukemia"},{"key":"R36-5-20210203","doi-asserted-by":"crossref","first-page":"7248","DOI":"10.1038\/sj.onc.1208850","article-title":"The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene.","volume":"24","author":"Bousquet","year":"2005","journal-title":"Oncogene"},{"key":"R37-5-20210203","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/sj.leu.2404104","article-title":"A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma.","volume":"20","author":"Adelaide","year":"2006","journal-title":"Leukemia"},{"key":"R38-5-20210203","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/gcc.20235","article-title":"A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11. 2) translocation in a patient with a clinically typical chronic myeloid leukemia.","volume":"44","author":"Griesinger","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"key":"R39-5-20210203","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2005-03-1183","article-title":"The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both \u201catypical\u201d myeloproliferative disorders and myelodysplastic syndromes.","volume":"106","author":"Steensma","year":"2005","journal-title":"Blood"},{"key":"R40-5-20210203","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.","volume":"106","author":"Jones","year":"2005","journal-title":"Blood"},{"key":"R41-5-20210203","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.leu.2404036","article-title":"Absence of the JAK2 V617F activating mutation in classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma.","volume":"20","author":"Melzner","year":"2006","journal-title":"Leukemia"},{"key":"R42-5-20210203","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/10428190500271723","article-title":"JAK2 V617F mutation is uncommon in non-Hodgkin lymphomas.","volume":"47","author":"Lee","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"R43-5-20210203","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1365-2141.2005.05697.x","article-title":"The V617F mutation in Jak2 is not found in childhood acute lymphoblastic leukaemia.","volume":"130","author":"Sulong","year":"2005","journal-title":"Br J Haematol"},{"key":"R44-5-20210203","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood-2005-05-1898","article-title":"The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.","volume":"106","author":"Levine","year":"2005","journal-title":"Blood"},{"key":"R45-5-20210203","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1080\/02841860500341223","article-title":"Absence of JAK2 V617F mutation in gastric cancers.","volume":"45","author":"Lee","year":"2006","journal-title":"Acta Oncol"},{"key":"R46-5-20210203","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/sj.onc.1209163","article-title":"The JAK2 V617F mutation in de novo acute myelogenous leukemias.","volume":"25","author":"Lee","year":"2006","journal-title":"Oncogene"},{"key":"R47-5-20210203","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2005-05-2087","article-title":"The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders.","volume":"106","author":"Scott","year":"2005","journal-title":"Blood"},{"key":"R48-5-20210203","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1365-2141.2005.05743.x","article-title":"Concomitant neutrophil JAK2 V617F mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia.","volume":"131","author":"Tefferi","year":"2005","journal-title":"Br J Haematol"},{"key":"R49-5-20210203","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1182\/blood-2005-05-1889","article-title":"Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2.","volume":"106","author":"Kralovics","year":"2005","journal-title":"Blood"},{"key":"R50-5-20210203","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0002-9343(96)00351-8","article-title":"Inapparent polycythemia vera\u2014an unrecognized diagnosis.","volume":"102","author":"Lamy","year":"1997","journal-title":"Am J Med"},{"key":"R51-5-20210203","first-page":"339","article-title":"Diagnosis and classification of the polycythemias.","volume":"12","author":"Berlin","year":"1975","journal-title":"Semin. Hematol"},{"key":"R52-5-20210203","first-page":"17","article-title":"World Health Organization Classification of Tumors: Tumours of the Haematopoietic and Lymphoid Tissues.","author":"Vardiman","year":"2001"},{"key":"R53-5-20210203","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1038\/sj.leu.2404379","article-title":"JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less?","volume":"20","author":"Verstovsek","year":"2006","journal-title":"Leukemia"},{"key":"R54-5-20210203","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","article-title":"Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.","volume":"110","author":"Tefferi","year":"2007","journal-title":"Blood"},{"key":"R55-5-20210203","doi-asserted-by":"crossref","first-page":"599","DOI":"10.4065\/82.5.599","article-title":"Evaluation of \u201cincreased\u201d hemoglobin in the JAK2 mutations era: a diagnostic algorithm based on genetic tests.","volume":"82","author":"Tefferi","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"R56-5-20210203","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1056\/NEJMp068293","article-title":"Jak2 mutations in polycythemia vera\u2013molecular mechanisms and clinical applications.","volume":"356","author":"Tefferi","year":"2007","journal-title":"N Engl J Med"},{"key":"R57-5-20210203","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/MOH.0b013e32801684d9","article-title":"The diagnostic interface between histology and molecular tests in myeloproliferative disorders.","volume":"14","author":"Tefferi","year":"2007","journal-title":"Curr Opin Hematol"},{"key":"R58-5-20210203","first-page":"368","article-title":"The value of bone marrow histology in differentiating between early stage polycythemia vera and secondary (reactive) polycythemias.","volume":"86","author":"Thiele","year":"2001","journal-title":"Haematologica"},{"key":"R59-5-20210203","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1038\/sj.leu.2404724","article-title":"Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera.","volume":"21","author":"Tefferi","year":"2007","journal-title":"Leukemia"},{"key":"R60-5-20210203","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1002\/cncr.22663","article-title":"Clinical correlates of JAK2V617F allele burden in essential thrombocythemia.","volume":"109","author":"Kittur","year":"2007","journal-title":"Cancer"},{"key":"R61-5-20210203","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.21645","article-title":"The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera.","volume":"106","author":"Tefferi","year":"2006","journal-title":"Cancer"},{"key":"R62-5-20210203","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1365-2141.2005.05776.x","article-title":"The JAK2 tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.","volume":"131","author":"Tefferi","year":"2005","journal-title":"Br J Haematol"},{"key":"R63-5-20210203","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2141.2005.05764.x","article-title":"JAK2 V617F mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance.","volume":"131","author":"Wolanskyj","year":"2005","journal-title":"Br J Haematol"},{"key":"R64-5-20210203","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/sj.leu.2404500","article-title":"Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients.","volume":"21","author":"Gangat","year":"2007","journal-title":"Leukemia"},{"key":"R65-5-20210203","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1055\/s-2007-976165","article-title":"Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F.","volume":"33","author":"Tefferi","year":"2007","journal-title":"Semin Thromb Hemost"},{"key":"R66-5-20210203","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1182\/blood-2007-01-066985","article-title":"The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia.","volume":"109","author":"Tefferi","year":"2007","journal-title":"Blood"},{"key":"R67-5-20210203","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1365-2141.2007.06674.x","article-title":"Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation.","volume":"138","author":"Gangat","year":"2007","journal-title":"Br J Haematol"},{"key":"R68-5-20210203","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/cncr.22630","article-title":"Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution.","volume":"109","author":"Tefferi","year":"2007","journal-title":"Cancer"},{"key":"R69-5-20210203","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2141.2006.06430.x","article-title":"The haematocrit and platelet target in polycythemia vera.","volume":"136","author":"Di Nisio","year":"2007","journal-title":"Br J Haematol"},{"key":"R70-5-20210203","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera.","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"key":"R71-5-20210203","first-page":"166","article-title":"Polycythemia Vera and the Myeloproliferative Disorders.","author":"Berk","year":"1995"},{"key":"R72-5-20210203","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood-2006-03-009860","article-title":"High molecular response rate of polycythemia vera patients treated with pegylated interferon \u03b1-2a.","volume":"108","author":"Kiladjian","year":"2006","journal-title":"Blood"},{"key":"R73-5-20210203","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1182\/blood-2006-05-025544","article-title":"Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter?","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"key":"R74-5-20210203","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N Engl J Med"},{"key":"R75-5-20210203","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"key":"R76-5-20210203","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1046\/j.1365-2141.1997.782714.x","article-title":"Identification of \u2018short-lived' and \u2018long-lived' patients at presentation of idiopathic myelofibrosis.","volume":"97","author":"Cervantes","year":"1997","journal-title":"Br J Haematol"},{"key":"R77-5-20210203","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","article-title":"Myelofibrosis with myeloid metaplasia.","volume":"342","author":"Tefferi","year":"2000","journal-title":"N Engl J Med"},{"key":"R78-5-20210203","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","article-title":"Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system.","volume":"88","author":"Dupriez","year":"1996","journal-title":"Blood"},{"key":"R79-5-20210203","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1046\/j.1365-2141.2001.02796.x","article-title":"Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia.","volume":"113","author":"Tefferi","year":"2001","journal-title":"Br J Haematol"},{"key":"R80-5-20210203","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/cncr.21644","article-title":"Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia.","volume":"106","author":"Dingli","year":"2006","journal-title":"Cancer"},{"key":"R82-5-20210203","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1038\/sj.leu.2404711","article-title":"Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions.","volume":"21","author":"Tefferi","year":"2007","journal-title":"Leukemia"},{"key":"R83-5-20210203","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1182\/blood-2006-02-004572","article-title":"Lenalidomide therapy in myelofibrosis with myeloid metaplasia.","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"key":"R84-5-20210203","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1038\/sj.leu.2404750","article-title":"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L\/K mutations.","volume":"21","author":"Pardanani","year":"2007","journal-title":"Leukemia"},{"key":"R85-5-20210203","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1634\/stemcells.2007-0175","article-title":"Extending JAK2V617F and MPLW515 Mutation Analysis to Single Hematopoietic Colonies and B- and T-lymphocytes.","volume":"25","author":"Pardanani","year":"2007","journal-title":"Stem Cells"},{"key":"R86-5-20210203","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1517\/13543784.15.12.1555","article-title":"Experimental therapy in myelofibrosis with myeloid metaplasia.","volume":"15","author":"Verstovsek","year":"2006","journal-title":"Expert Opin Investig Drugs"},{"key":"R87-5-20210203","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood-2006-03-009746","article-title":"International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PPO.0b013e318159467b","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:39:05Z","timestamp":1786034345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00130404-200711000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":86,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0b013e318159467b","relation":{},"ISSN":["1528-9117"],"issn-type":[{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2007,11]]}}}